02230nas a2200421   4500000000100000008004100001260001300042653001500055653001000070653002900080653002400109653001100133653002300144653001200167653002000179653002600199653000900225653000900234653001500243653001300258653001800271653002000289100001400309700001600323700001200339700001600351700001400367700001500381700001300396700001900409700001200428700001600440245011600456300000900572490000600581520120700587022001401794       1980                            d  c1980 Jun10aAdolescent10aAdult10aClinical Trials as Topic10aDouble-Blind Method10aHumans10aImmunity, Cellular10aleprosy10aLeukocyte Count10aLymphocyte Activation10aMale10aSkin10aSkin Tests10aSulfones10aT-Lymphocytes10aTransfer Factor1 aLeser P G1 aMargarido L1 aBelda W1 aSartori S G1 aHares W A1 aFreire C A1 aFleury R1 aMontenegro M R1 aLeser W1 aNaspitz C K00aCell mediated immunity in patients with Virchowian hanseniasis before and after treatment with transfer factor.  a3-270 v53 a<p>Cell mediated immunity (CMI), bacterial index (BI), morphological index (MI), skin and lymph nodes biopsies were evaluated in 15 patients with virchowian hanseniasis before and after treatment with transfer factor (TF) obtained from human spleens. The patients were divided in 3 groups: group I (control) received only sulfone, group II received sulfone plus TF and group III received only TF. There was no difference in the numbers of peripherical T and B lymphocytes of patients and normal controls. Before the treatment with TF, there was an impaired response of the patient's peripheral lymphocytes to PHA stimulus, in the presence of autologous or homologous plasma. This depressed response was corrected after treatment with TF in the patients of group III. In none of the patients a positive Mitsuda reaction was observed before and after treatment with TF. The improvement of the MI observed in group III, treated only with TF was remarkably similar to the patients treated only with sulfone. This work points out that TF has a role in the treatment of patients with virchowian hanseniasis, based on the improvement of CMI, MI, on histopathology of skin biopsies and clinical conditions.</p>  a0100-3283